CTRI/2023/03/050239已完成Unknown
A Clinical Study to Evaluate Safety, Efficacy and In-Use Tolerability Study of HDSC-022209 in Healthy Adult Human Subjects in Reduction in Facial dark Spots.
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1)Age: 18 to 55 years (both inclusive) at the time of consent.
- •2)Sex: Healthy non-pregnant/non-lactating females and Males.
- •3)Subject has facial dark spots preferably equal ratio of tan, blemishes, sunspots, and age spots.
- •4)Female of childbearing potential must have a reported negative pregnancy during screening.
- •5)Subject is generally in good health.
- •6)Subject is not undergone any cosmetic procedures or any medication for the treatment of acne 3 months prior to study enrolment.
- •7)Subject is able to follow their normal skin care routines and to refrain from introducing any new skin care products during the study.
- •8)Willing to forgo use of all other topical acne medications or antibiotics during the study period or any treatment duration of the study
- •9)Subject is able to forgo changes in baseline medications and nutritional supplements, any other anti-acne facial cream, powder, face mask etc. during the study period.
- •10)If the female subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.
- •11)Subject is willing not to introduce any new soaps, cleansers, lotions, creams, or any other face product etc. for the duration of the study.
- •12)Subject is willing to give written informed consent and are willing to follow the study procedure.
- •13)The subject is willing to use test product throughout the study period.
排除标准
- •1)Subject has a history of allergy or sensitivity to the test product ingredients.
- •2)Subject who has a history of allergy with products containing turmeric or any known ingredients.
- •3)Subject who has pre-existing or dormant dermatologic conditions (e.g., psoriasis rashes, eczema, seborrheic dermatitis, acne, acne rosacea or any other) that could interfere with the subject selection and outcome of the study as determined by the Investigator.
- •4)Subject has taken any systemic therapy with chronic antibiotic therapy, retinoids, and/or oral steroids during the 4 weeks prior to the start or anticipates having to use at any point during the study.
- •5)Subject using any topical retinoids within 2 weeks of the screening visit or anticipates having to use at any point during the study.
- •6)Subject is not willing to avoid unprotected sun or other UV radiation exposure during the study period.
- •7)Subject has a history of alcohol or drug addiction.
- •8)Subject has a history of prior use of scar removal, spots reduction, skin radiance or wrinkles laser treatment within 3 months.
- •9)Any other condition which could warrant exclusion from the study, as per the dermatologistâ??s/Investigatorâ??s discretion.
- •10)Subject has a history of chronic illness which may influence the cutaneous state.
- •11)Subjects participating in other similar cosmeceuticals, cosmetics or therapeutic trials or skin care products within the last 4 weeks.
研究者
相似试验
已完成
1 期
A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis bullosa patients.dystrophic epidermolysis bullosaJPRN-UMIN000028366Ishin Pharmaceutical Co. Ltd.5
已完成
2 期
A Clinical Evaluation of Piloset Tablet Piloset Cream in Patients suffering from Internal Hemorrhoids.CTRI/2014/01/004300ARJUN HEALTHCARE30
招募中
1 期
Evaluate The Efficacy And Safety Of HMTG-122106 In ChildreCTRI/2023/07/054858Himalaya Wellness Company
尚未招募
3 期
Result of Psorlyn tablet and Psorlyn oil in Psoriasis(skin disease).CTRI/2021/04/033243DrVasishths Ayuremedies
尚未招募
1 期
To Evaluate The Efficacy And Safety Of HSGM-122104 Inchildren in (Healthy Human Volunteers)CTRI/2023/07/054999Himalaya Wellness Company